| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.48▲ | 2.47▲ | 2.45▲ | 2.49▼ | 2.23▲ |
| MA10 | 2.48▲ | 2.44▲ | 2.43▲ | 2.26▲ | 2.20▲ |
| MA20 | 2.48▲ | 2.43▲ | 2.47▲ | 2.21▲ | 2.29▲ |
| MA50 | 2.44▲ | 2.51▼ | 2.42▲ | 2.21▲ | 3.53▼ |
| MA100 | 2.43▲ | 2.38▲ | 2.21▲ | 2.29▲ | 6.93▼ |
| MA200 | 2.46▲ | 2.21▲ | 2.21▲ | 2.83▼ | 7.97▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.013▲ | -0.006▼ | 0.054▲ | 0.140▲ |
| RSI | 59.516▲ | 55.530▲ | 54.347▲ | 58.105▲ | 47.637▼ |
| STOCH | 38.889 | 70.326 | 55.243 | 75.634 | 38.801 |
| WILL %R | -50.000 | -14.706▲ | -30.952 | -27.551 | -34.562 |
| CCI | -21.046 | 120.098▲ | 64.391 | 67.467 | 119.072▲ |
|
Thursday, November 13, 2025 05:45 AM
Latest data shows the largest indicative borrow rate increases among liquid option names include: Forward Industries (FORD) 307.94% +12.72, ...
|
|
Tuesday, November 11, 2025 03:45 AM
Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales. Though it's unprofitable, ...
|
|
Tuesday, November 11, 2025 02:15 AM
Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/11/25 | 2.35 | 2.52 | 2.34 | 2.47 | 16,037,100 |
| 13/11/25 | 2.52 | 2.56 | 2.41 | 2.41 | 11,197,672 |
| 12/11/25 | 2.64 | 2.72 | 2.47 | 2.54 | 14,693,787 |
| 11/11/25 | 2.41 | 2.74 | 2.35 | 2.65 | 26,803,200 |
| 10/11/25 | 2.42 | 2.60 | 2.35 | 2.37 | 23,976,000 |
| 07/11/25 | 2.25 | 2.38 | 2.08 | 2.30 | 29,589,500 |
| 06/11/25 | 2.26 | 2.51 | 2.11 | 2.31 | 83,539,930 |
| 05/11/25 | 1.83 | 1.87 | 1.76 | 1.81 | 17,393,937 |
| 04/11/25 | 1.88 | 1.93 | 1.805 | 1.82 | 15,935,086 |
| 03/11/25 | 2.16 | 2.20 | 1.86 | 1.95 | 50,937,000 |
|
|
||||
|
|
||||
|
|